ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology

Oncotarget

Volumn 8, Issue 3, 2017, Pages 4914-4921

  Petrini, Iacopo ^a   Barachini, Serena ^a   Carnicelli, Vittoria ^a   Galimberti, Sara ^a   Modeo, Letizia ^a   Boni, Roberto ^a   Sollini, Martina ^b   Erba, Paola Anna ^a  

^a UNIVERSITY OF PISA   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

Author keywords

ED B; Endothelial to mesenchymal transition; Fibronectin; Prostate cancer; TGF

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; FIBRONECTIN; NERVE CELL ADHESION MOLECULE; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN; CYTOKINE; FN1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DU145 CELL LINE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STROMA CELL; MULTIPOTENT MESANGIOGENIC PROGENITOR CELL; MULTIPOTENT STEM CELL; PC3 CELL LINE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; DISEASE EXACERBATION; DRUG EFFECT; GENE EXPRESSION REGULATION; MESENCHYMAL STEM CELL; METABOLISM; METASTASIS; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MESENCHYMAL STEM CELLS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 85011967161     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13615     Document Type: Article

References (34)

1. To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis & tissue repair. 2011; 4:21.
2. Jaalouk DE, Lammerding J. Mechanotransduction gone awry. Nature reviews Molecular cell biology. 2009; 10:63-73.
3. White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. The Journal of pathology. 2008; 216:1-14.
4. Chauhan AK, Iaconcig A, Baralle FE, Muro AF. Alternative splicing of fibronectin: a mouse model demonstrates the identity of in vitro and in vivo systems and the processing autonomy of regulated exons in adult mice. Gene. 2004; 324:55-63.
5. Peters JH, Hynes RO. Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. Cell adhesion and communication. 1996; 4:103-125.
6. Magnuson VL, Young M, Schattenberg DG, Mancini MA, Chen DL, Steffensen B, Klebe RJ. The alternative splicing of fibronectin pre-mRNA is altered during aging and in response to growth factors. The Journal of biological chemistry. 1991; 266:14654-14662.
7. Ffrench-Constant C, Hynes RO. Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. Development. 1989; 106:375-388.
8. Laitinen L, Vartio T, Virtanen I. Cellular fibronectins are differentially expressed in human fetal and adult kidney. Laboratory investigation. 1991; 64:492-498.
9. White ES, Muro AF. Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models. IUBMB life. 2011; 63:538-546.
10. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer research. 2006; 66:11089-11093.
11. Kosmehl H, Berndt A, Katenkamp D. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Virchows Archiv. 1996; 429:311-322.
12. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. International journal of cancer. 1994; 59:11-16.
13. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. International journal of cancer. 1994; 59:612-618.
14. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Durkop H, Menssen HD. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009; 113:2265-2274.
15. Locher R, Erba PA, Hirsch B, Bombardieri E, Giovannoni L, Neri D, Durkop H, Menssen HD. Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient. Journal of cancer research and clinical oncology. 2014; 140:35-43.
16. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer. 2002; 2:442-454.
17. Weinberg RA. Mechanisms of malignant progression. Carcinogenesis. 2008; 29:1092-1095.
18. Tse JC, Kalluri R. Mechanisms of metastasis: epithelialto-mesenchymal transition and contribution of tumor microenvironment. Journal of cellular biochemistry. 2007; 101:816-829.
19. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. Journal of cellular physiology. 2007; 213:374-383.
20. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nature reviews Molecular cell biology. 2006; 7:131-142.
21. Tran NL, Nagle RB, Cress AE, Heimark RL. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. The American journal of pathology. 1999; 155:787-798.
22. Nalla AK, Estes N, Patel J, Rao JS. N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Experimental cell research. 2011; 317:2512-2521.
23. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. The Journal of cell biology. 2006; 172:973-981.
24. Midulla M, Verma R, Pignatelli M, Ritter MA, Courtenay-Luck NS, George AJ. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer research. 2000; 60:164-169.
25. Berndt A, Borsi L, Luo X, Zardi L, Katenkamp D, Kosmehl H. Evidence of ED-B+ fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupuytren). Histochemistry and cell biology. 1998; 109:249-255.
26. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. The EMBO journal. 1987; 6:2337-2342.
27. Freire-de-Lima L, Gelfenbeyn K, Ding Y, Mandel U, Clausen H, Handa K, Hakomori SI. Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:17690-17695.
28. Ding Y, Gelfenbeyn K, Freire-de-Lima L, Handa K, Hakomori SI. Induction of epithelial-mesenchymal transition with O-glycosylated oncofetal fibronectin. FEBS letters. 2012; 586:1813-1820.
29. Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert opinion on therapeutic targets. 2005; 9:491-500.
30. Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, Bombardieri E, Grana C, Giovannoni L, Neri D, Menssen HD, Mariani G. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. Journal of nuclear medicine. 2012; 53:922-927.
31. Petrini M, Pacini S, Trombi L, Fazzi R, Montali M, Ikehara S, Abraham NG. Identification and purification of mesodermal progenitor cells from human adult bone marrow. Stem cells and development. 2009; 18:857-866.
32. Fazzi R, Pacini S, Carnicelli V, Trombi L, Montali M, Lazzarini E, Petrini M. Mesodermal progenitor cells (MPCs) differentiate into mesenchymal stromal cells (MSCs) by activation of Wnt5/calmodulin signalling pathway. PloS one. 2011; 6:e25600.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.
34. Trombi L, Pacini S, Montali M, Fazzi R, Chiellini F, Ikehara S, Petrini M. Selective culture of mesodermal progenitor cells. Stem cells and development. 2009; 18:1227-1234.